Abstract:IMPORTANCE:Studies of the use of gonadotropin-releasing hormone analogs (GnRHa) to protect ovarian function have shown mixed results.OBJECTIVE:To determine whether administering GnRHa during chemotherapy in premenopausal women with breast cancer can reduce ovarian impairment.DESIGN, SETTING, AND PARTICIPANTS:This randomized clinical trial, conducted at the Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital and Zhejiang Cancer Hospital in China, was an open-label trial involving premenopausal women aged 18 to 49 years with operable stage I to III breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned in 2 parallel groups: treatment with chemotherapy with or without GnRHa. Enrollment occurred from September 2015 to August 2017, and follow-up ended December 2020. The data were analyzed in March 2021. A total of 405 patients were enrolled in the study, among whom 27 patients (6.7%) quit participation voluntarily, 33 (8.1%) did not meet the inclusion criteria and were excluded, and 15 (3.7%) were lost to follow-up. Ultimately 330 patients were included in the primary analysis, including 29 patients with baseline anti-Müllerian hormone levels less than 0.5ng/ mL.INTERVENTIONS:Eligible patients were randomly assigned (1:1) to receive chemotherapy with (n = 165) or without (n = 165) GnRHa. In patients randomized to receive GnRHa, 3.6 mg of goserelin or 3.75 mg of leuprorelin was injected subcutaneously once every 28 days from 1 to 2 weeks before the first cycle of chemotherapy to 4 weeks after the last cycle of chemotherapy.MAIN OUTCOMES AND MEASURES:The primary end point was the rate of premature ovarian insufficiency (POI) at 12 months after chemotherapy. Premature ovarian insufficiency was defined as anti-Müllerian hormone levels of less than 0.5 ng/mL in this study. The secondary end point was overall survival (OS) and tumor-free survival (TFS).RESULTS:A total of 330 eligible patients could be evaluated with complete data, among whom 301 patients (91.2%; GnRHA group: mean [SD] age, 40.6 [6.7] years; control group: mean [SD] age, 40.2 [5.9] years) were eligible for primary end point analysis. At 12 months after the completion of chemotherapy, the POI rate was 10.3% (15 of 146) in the GnRHa group and 44.5% (69 of 155) in the control group (odds ratio, 0.23; 95% CI, 0.14-0.39; P < .001). Anti-Müllerian hormone resumption in the GnRHa group was significantly better than that in the control group (15 of 25 vs 6 of 44; odds ratio, 4.40; 95% CI, 1.96-9.89; P < .001). After a median follow-up of 49 months (range, 25-60 months), the differences in 4-year OS and TFS between the 2 groups were not significant. A post hoc analysis showed that in patients younger than 35 years, the TFS was higher in the GnRHa group than in the control group (93% vs 62%; P = .004; hazard ratio, 0.15; 95% CI, 0.03-0.82; P = .03).CONCLUSIONS AND RELEVANCE:This randomized clinical trial found that administering GnRHa in treatment with chemotherapy for premenopausal patients with breast cancer reduces the risk of POI, which promotes the recovery of ovarian function.TRIAL REGISTRATION:ClinicalTrials.gov Identifier: NCT02518191.

Goserelin versus ovarian surgery castration in premenopausal patients with advanced breast cancer:A meta-analysis

EFFICACY OF GOSERELIN FOR POST-OPERATIVE TREATMENT IN CHINESE PATIENTS WITH MODERATE TO SEVERE ENDOMETRIOSIS: AN OBSERVATIONAL, MULTICENTRE, OPEN-LABEL, NON-INTERVENTIONAL STUDY

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage Ii/Iii Hormone Receptor-Positive Breast Cancer Without Chemotherapy-Induced Amenorrhea

Role of goserelin in combination with endocrine therapy for the treatment of advanced breast cancer in premenopausal women positive for hormone receptor: a retrospective matched case-control study.

Goserelin Combined with Letrozole in the Treatment of Premenopausal Patients with Metastatic Breast Cancer

Goserelin Plus Tamoxifen Versus Tamoxifen Alone, in Pre-Menopausal or Peri-Menopausal Patients with Hormone Receptor-Positive Early-Stage Breast Cancer: A Randomised Controlled Trial in China

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women with Breast Cancer in China: A Randomized Clinical Trial.

Gonadotropin-Releasing Hormone Agonists During Gonadal Chemotherapy for the Effect on Pregnancy Outcome and Ovarian Function in Premenopausal Patients With Breast Cancer: A Systematic Review and Meta-Analysis

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China

Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial

Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.

Combined Effects of Goserelin and Tamoxifen on Estradiol Level, Breast Density, and Endometrial Thickness in Premenopausal and Perimenopausal Women with Early-Stage Hormone Receptor-Positive Breast Cancer: a Randomised Controlled Clinical Trial.

Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer

Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study

Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.

Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)

Clinical efficacy and safety of trimonthly administration of goserelin acetate 10.8 mg in premenopausal Chinese females with symptomatic adenomyosis: a prospective cohort study

Ovarian protection and safety of gonadotropin-releasing hormone agonist after cervical cancer surgery: systematic review and meta-analysis

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial

A randomized study comparing the side effects and hormonal status of triptorelin and leuprorelin following conservative laparoscopic surgery for ovarian endometriosis in Chinese women